INCA033989 Shows Promise in mutCALR-Driven Myeloproliferative Neoplasms
- Here's a breakdown of the key findings from the provided text, focusing on the study results regarding INCA033989 treatment for myeloproliferative neoplasms (MPNs):
- * Strong Correlation: There was a strong correlation (r² = 0.97) between CALR mutation measures in bone marrow and peripheral blood samples.
- In essence, the study suggests that INCA033989 effectively targets cells with the CALR mutation, leading to clinical improvements in both ET and MF patients, and potentially modifying...
Here’s a breakdown of the key findings from the provided text, focusing on the study results regarding INCA033989 treatment for myeloproliferative neoplasms (MPNs):
Key Findings:
* Strong Correlation: There was a strong correlation (r² = 0.97) between CALR mutation measures in bone marrow and peripheral blood samples.
* Somatic Mutations: Nondriver somatic mutations were found in 33% of Essential Thrombocythemia (ET) patients and 83% of Myelofibrosis (MF) patients. MF patients had a higher number of co-occurring variants (0-9) compared to ET patients (0-3).
* TET2 and ASXL1, TET2 and EZH2: These were the most frequently mutated genes identified.
* CALR Mutation Reduction in ET:
* 95% of ET patients (37/39 with longitudinal data) showed a reduction in CALR mutation.
* 56% (22/39) achieved molecular response (meaning a significant reduction in the mutated gene).
* 88% of patients achieving durable remission (based on blood counts) also achieved molecular response.
* CALR Mutation Reduction in MF:
* 37% of MF patients (10/17 with evaluable spleen response) experienced a 25% reduction in spleen volume. All of these patients also had a reduction in CALR mutation and 50% achieved molecular response.
* 57% of MF patients (12/21) achieved anemia response, all with VAF reduction, and 33% achieved molecular response.
* Selective Targeting: The treatment selectively reduced CALR-mutated hematopoietic stem/progenitor cells (HSPCs) and decreased the density of total megakaryocytes (MKs).
* Conclusion: The investigators concluded that a rapid and selective reduction in CALR-mutated HSPCs and MKs correlated with clinical responses,suggesting potential disease modification and recovery of normal blood cell production.
In essence, the study suggests that INCA033989 effectively targets cells with the CALR mutation, leading to clinical improvements in both ET and MF patients, and potentially modifying the disease course.